PWS
MRNA icon

Precision Wealth Strategies’s Moderna MRNA Stock Holding History

Precision Wealth Strategies’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,796
Closed -$340K – 101
2023
Q2 		$340K Sell
2,796
-243
-8% -$32.4K 0.56% 39
2023
Q1 		$467K Sell
3,039
-361
-11% -$59.6K 0.73% 29
2022
Q4 		$611K Sell
3,400
-1,930
-36% -$316K 0.64% 25
2022
Q3 		$709K Sell
5,330
-3,696
-41% -$561K 0.63% 28
2022
Q2 		$1.55M Sell
9,026
-5
-0.1% -$715 1.22% 15
2022
Q1 		$1.56M Buy
9,031
+4,110
+84% +$692K 0.92% 16
2021
Q4 		$1.25M Buy
4,921
+20
+0.4% +$5.85K 0.9% 21
2021
Q3 		$1.89M Sell
4,901
-200
-4% -$73.8K 1.46% 12
2021
Q2 		$1.2M Sell
5,101
-1,119
-18% -$200K 1.03% 19
2021
Q1 		$815K Sell
6,220
-231
-4% -$33.5K 0.78% 16
2020
Q4 		$674K Buy
+6,451
New +$653K 0.73% 13

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Precision Wealth Strategies's MRNA Position: Q3 2023 in Review

Precision Wealth Strategies sold out of Moderna (MRNA) in Q3 2023, closing a stake of 2,796 shares — an estimated $340K sold.

Precision Wealth Strategies first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $1.89M in Q3 2021. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Precision Wealth Strategies reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Precision Wealth Strategies sold 2,796 Moderna shares in Q3 2023, an estimated $340K.
  • Precision Wealth Strategies first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • Precision Wealth Strategies's Moderna position peaked at $1.89M in Q3 2021.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Precision Wealth Strategies's 13F filing for Q3 2023, filed 31 Oct 2023.